Carterra

Summary

Carterra builds high-throughput surface plasmon resonance (SPR) instruments — chiefly the LSA family and newer Vega/Ultra platforms — for monoclonal-antibody discovery and characterization. The company's own 2017 rename release states it was Wasatch Microfluidics, Inc. until 2017-05-01, when it became Carterra, Inc.; that release also says the company was founded in 2005 and is based in Salt Lake City (rename announcement). Its homepage lists 825 N. 300 W. Ste. C309, Salt Lake City, UT 84103 (official site).

The Utah origin is documented outside the company's marketing: a University of Utah Lassonde Entrepreneur Institute profile says the firm formed on the U campus in 2004 from mechanical-engineering professor Bruce Gale's work, with Josh Eckman developing it through the Lassonde New Venture Development Center (Lassonde profile). The profile predates the Carterra name and does not state a legal incorporation date.

Impact

Antibody therapeutics depend on knowing how candidates bind — kinetics, affinity, and epitope diversity — early enough to choose the right clones from large libraries. Carterra's instruments sit in that characterization step. The company's 2017 release describes array-based SPRi detection coupled to microfluidics for high-throughput mAb library screening (rename announcement).

Independent of company copy, a 2020 PLOS ONE industry collaboration measured anti-PD-1 antibody binding kinetics on a Carterra LSA and compared results to a Biacore 8K, reporting near-identical rate and affinity constants on flat sensor chips and using the LSA for epitope binning across the panel (PD-1 landscape paper). That paper is evidence the platform is used in pharmaceutical antibody-characterization work, not merely sold for it — though it validates one instrument class in one therapeutic area, not market share.

Bet: that making SPR truly high-throughput — hundreds of parallel interactions per run — shifts antibody discovery from triaging a few clones to characterizing whole libraries, and that the bottleneck moved from "can we measure binding?" to "can we measure all of them?"

The honest counterweight: this is a tools vendor to drug discovery, not a therapeutic developer; impact is indirect and concentrated in labs that can afford specialized biosensor platforms. No third-party measure of how widely deployed Carterra systems are appears in the captured sources.

Utah Context

Carterra is a documented University of Utah spinout lineage: campus formation in 2004, Lassonde commercialization programs, and continued Salt Lake City headquarters on the company's own site. It connects the wiki's health-bio instrument makers to the U's mechanical-engineering and entrepreneurship pipeline.

What They Need Now

The company's homepage and careers navigation point to instrument sales, applications support, and software for kinetics and epitope analysis — roles spanning biophysics applications scientists, microfluidics and optical hardware engineers, and software for high-throughput biosensor data (official site). Specific open requisitions were not captured here.

Open Questions

• No corporate identifier resolved. No utah-entity, ein, or SEC record has been pulled; a Utah Division of Corporations search could confirm the Wasatch Microfluidics → Carterra legal-entity continuity and incorporation date.
• Founding year conflict. The 2017 company release says founded 2005; the Lassonde profile describes campus formation in 2004. Both may be true (idea/team vs incorporation) but the wiki does not have a registry record to reconcile them.
• Market position is unverified. Superlatives on the company site ("highest-throughput SPR platforms on the market") are self-reported. The peer-reviewed source validates instrument use in one study; it does not establish share of pharma antibody-screening labs.
• Headcount and revenue are not stated on the captured homepage.

Evidence

• Source: Carterra Official Website · https://carterra-bio.com/
• Source: Wasatch Microfluidics Announces Name Change to Carterra (2017) · https://carterra-bio.com/news/wasatch-microfluidics-announces-name-change-to-carterra-inc-and-new-high-throughput-spr-instrument/
• Source: Lassonde — Wasatch Microfluidics Profile · https://lassonde.utah.edu/wasatch-microfluidics-from-the-lassonde-institute-to-pfizer-research-offices/
• Source: Assessing the Binding Properties of the anti-PD-1 Antibody Landscape (2020) · https://doi.org/10.1371/journal.pone.0229206